The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Open accessAbstract
Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell malignancy, have dramatically improved. The development of the immunomodulatory drugs (IMiDs), which include thalidomide, lenalidomide, and pomalidomide, has contributed significantly to these improved outcomes. While thalidomide is now less commonly prescribed, lenalidomide is widely used in the treatment of newly diagnosed transplant-eligible and transplant-ineligible patients, in the maintenance setting post-transplant and in the relapsed/refractory setting, while pomalidomide is currently utilized in the relapsed/refractory setting. The IMiDs have been reported to have a multitude of activities, including anti-angiogenic, cytotoxic, and immunomodulatory. However, the more recent discoveries that the IMiDs bind to cereblon and thus regulate the ubiquitination of key transcription factors including IKZF1 and IKZF3 have provided greater insight into their mechanism of action. Here, the clinical efficacy of these agents in myeloma is reviewed and the structure-function relationship, the molecular mechanisms of action, and the association of IMiDs with second primary malignancies and thrombosis are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · cited 2×
“This observation prompted a phase II study in 84 patients with refractory disease [10].”
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · cited 1×
“While daratumumab has impressive single agent activity in heavily treated relapsed/refractory patients (overall response rates of 29–36%) [151, 152], recent studies have demonstrated even better activity when combined with either lenalidomide [66, 153] or pomalidomide [85].”
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332 · cited 1×
“Carfilzomib [68] 20 1–3 12–13 87 vs 67 (p\ 0.”
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Self-citationTHALIDOMIDE AND CONGENITAL ABNORMALITIES
Mcbride, W. G. (1961) · The Lancet · doi:10.1016/s0140-6736(61)90927-8 · Cited by 1,141
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · cited 1×
“While daratumumab has impressive single agent activity in heavily treated relapsed/refractory patients (overall response rates of 29–36%) [151, 152], recent studies have demonstrated even better activity when combined with either lenalidomide [66, 153] or pomalidomide [85].”
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060 · cited 1×
“Ixazomib [70] 12 1–3 17–21 78 vs 72 (p = 0.”
de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Krejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 954
Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933 · cited 2×
“A study comparing ‘high-dose’ dexamethasone (40 mg days 1–4, 9–12, 17–20 of a 28-day cycle) with ‘low-dose’ dexamethasone (40 mg days 1, 8, 15, 22 of a 28-day cycle) in combination with lenalidomide revealed a better 1-year OS rate with an improved sideeffect profile for the low-dose weekly dexamethasone [43].”
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Facon, T., Mary, J. Y., Hulin, C., Benboubker, L., Attal, M., Pegourie, B., Renaud, M., Harousseau, J. L., Guillerm, G., Chaleteix, C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61537-2 · Cited by 869
Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Palumbo, A., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G., San Miguel, J., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2405062 · Cited by 840
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68338-4 · Cited by 809
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793 · cited 1×
“The incidence of SPMs was 3% in patients on continuous lenalidomide/dexamethasone, 6% in the 18-cycle group, and 5% in the MPT group [188].”
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
Palumbo, A., Cavallo, F., Gay, F., Di Raimondo, F., Ben Yehuda, D., Petrucci, M. T., Pezzatti, S., Caravita, T., Cerrato, C., Ribakovsky, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402888 · Cited by 778
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Palumbo, A., Hajek, R., Delforge, M., Kropff, M., Petrucci, M. T., Catalano, J., Gisslinger, H., Wiktor-Jędrzejczak, W., Zodelava, M., Weisel, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112704 · Cited by 741
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · PubMed · Cited by 729
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669
Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease
Kim, J. H., & Scialli, A. R. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr088 · Cited by 659
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D. I., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 656
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Gandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12708 · Cited by 619
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607
Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma
Weber, D., Rankin, K., Gavino, M., Delasalle, K., & Alexanian, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.139 · Cited by 566
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Hsi, E. D., Steinle, R., Balasa, B., Szmania, S., Draksharapu, A., Shum, B. P., Huseni, M., Powers, D., Nanisetti, A., Zhang, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4246 · Cited by 559
Gupta, D., Treon, S., Shima, Y., Hideshima, T., Podar, K., Tai, Y., Lin, B., Lentzsch, S., Davies, F., Chauhan, D., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402295 · Cited by 553
Thalidomide in the treatment of lepra reactions
Sheskin, J. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563303 · Cited by 533
Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2874 · Cited by 531
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521 · cited 1×
“Daratumumab is an anti-CD38 monoclonal antibody which induces myeloma cell death via a variety of mechanisms including ADCC, antibody-dependent cellular phagocytosis, apoptosis, and inhibition of CD38 enzymatic activity [149, 150].”
Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Tai, Y.-T., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2008) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 473
DCAFs, the Missing Link of the CUL4-DDB1 Ubiquitin Ligase
Lee, J., & Zhou, P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.001 · Cited by 460
Wu, L., Adams, M., Carter, T., Chen, R., Muller, G., Stirling, D., Schafer, P., & Bartlett, J. B. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4405 · Cited by 440
Jakubowiak, A. J., Dytfeld, D., Griffith, K. A., Lebovic, D., Vesole, D. H., Jagannath, S., Al-Zoubi, A., Anderson, T., Nordgren, B., Detweiler-Short, K., et al. (2012) · Blood · doi:10.1182/blood-2012-04-422683 · Cited by 423
Galustian, C., Meyer, B., Labarthe, M.-C., Dredge, K., Klaschka, D., Henry, J., Todryk, S., Chen, R., Muller, G., Stirling, D., et al. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0620-4 · Cited by 391
Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538835 · Cited by 381
THALIDOMIDE AND CONGENITAL ABNORMALITIES
Lenz, W., Pfeiffer, R. A., Kosenow, W., & Hayman, D. J. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92665-x · Cited by 379
The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia
Bergsagel, D. E., Bailey, A. J., Langley, G. R., MacDonald, R. N., White, D. F., & Miller, A. B. (1979) · New England Journal of Medicine · doi:10.1056/nejm197910043011402 · Cited by 376
Morgan, B., Sun, L., Avitahl, N., Andrikopoulos, K., Ikeda, T., Gonzales, E., Wu, P., Neben, S., & Georgopoulos, K. (1997) · The EMBO Journal · doi:10.1093/emboj/16.8.2004 · Cited by 367
Zonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K. (2012) · Blood · doi:10.1182/blood-2011-06-360552 · Cited by 342
THALIDOMIDE AND CONGENITAL ABNORMALITIES
Burley, D. M., & Lenz, W. (1962) · The Lancet · doi:10.1016/s0140-6736(62)91217-5 · Cited by 324
Palumbo, A., Cavo, M., Bringhen, S., Zamagni, E., Romano, A., Patriarca, F., Rossi, D., Gentilini, F., Crippa, C., Galli, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6844 · Cited by 323
Palumbo, A., Falco, P., Corradini, P., Falcone, A., Di Raimondo, F., Giuliani, N., Crippa, C., Ciccone, G., Omedè, P., Ambrosini, M. T., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3463 · Cited by 319
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Lacy, M. Q., Hayman, S. R., Gertz, M. A., Dispenzieri, A., Buadi, F., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6802 · Cited by 317
Schey, S. A., Fields, P., Bartlett, J. B., Clarke, I. A., Ashan, G., Knight, R. D., Streetly, M., & Dalgleish, A. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.052 · Cited by 314
Cavo, M., Pantani, L., Petrucci, M. T., Patriarca, F., Zamagni, E., Donnarumma, D., Crippa, C., Boccadoro, M., Perrone, G., Falcone, A., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408898 · Cited by 308
Ellison, D. (1966) · The Lancet · doi:10.1016/s0140-6736(66)92099-x · Cited by 308
Clinical pharmacology of thalidomide
Eriksson, T., Björkman, S., & Höglund, P. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100320 · Cited by 299
Wang, M., Fayad, L., Wagner-Bartak, N., Zhang, L., Hagemeister, F., Neelapu, S. S., Samaniego, F., McLaughlin, P., Fanale, M., Younes, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70200-0 · Cited by 297
Lonial, S., Vij, R., Harousseau, J.-L., Facon, T., Moreau, P., Mazumder, A., Kaufman, J. L., Leleu, X., Tsao, L. C., Westland, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2649 · Cited by 296
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
LeBlanc, R., Hideshima, T., Catley, L. P., Shringarpure, R., Burger, R., Mitsiades, N., Mitsiades, C., Cheema, P., Chauhan, D., Richardson, P. G., et al. (2004) · Blood · doi:10.1182/blood-2003-02-0361 · Cited by 289
Palumbo, A., Bringhen, S., Kumar, S. K., Lupparelli, G., Usmani, S., Waage, A., Larocca, A., van der Holt, B., Musto, P., Offidani, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70609-0 · Cited by 289
Self-citationLarocca, A., Cavallo, F., Bringhen, S., Di Raimondo, F., Falanga, A., Evangelista, A., Cavalli, M., Stanevsky, A., Corradini, P., Pezzatti, S., et al. (2012) · Blood · doi:10.1182/blood-2011-03-344333 · Cited by 288
Thalidomide and dexamethasone combination for refractory multiple myeloma
Dimopoulos, M. A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., Vervessou, E., Samantas, E., Papadimitriou, C., Economou, O., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011132808904 · Cited by 283
Kyle, R. A., Pierre, R. V., & Bayrd, E. D. (1970) · New England Journal of Medicine · doi:10.1056/nejm197011192832101 · Cited by 283
Chang, D. H., Liu, N., Klimek, V., Hassoun, H., Mazumder, A., Nimer, S. D., Jagannath, S., & Dhodapkar, M. V. (2006) · Blood · doi:10.1182/blood-2005-10-4184 · Cited by 271
Kumar, S. K., Berdeja, J. G., Niesvizky, R., Lonial, S., Laubach, J. P., Hamadani, M., Stewart, A. K., Hari, P., Roy, V., Vescio, R., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71125-8 · Cited by 262
Kristinsson, S. Y., Pfeiffer, R. M., Björkholm, M., Goldin, L. R., Schulman, S., Blimark, C., Mellqvist, U.-H., Wahlin, A., Turesson, I., & Landgren, O. (2010) · Blood · doi:10.1182/blood-2009-11-252072 · Cited by 255
The Saga of Thalidomide: Neuropathy to Embryopathy, with Case Reports of Congenital Anomalies
Mellin, G. W., & Katzenstein, M. (1962) · New England Journal of Medicine · doi:10.1056/nejm196212062672305 · Cited by 252
Eriksson, T., Bjöurkman, S., Roth, B., Fyge, Å., & Höuglund, P. (1995) · Chirality · doi:10.1002/chir.530070109 · Cited by 251
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
Ruan, J., Martin, P., Shah, B., Schuster, S. J., Smith, S. M., Furman, R. R., Christos, P., Rodriguez, A., Svoboda, J., Lewis, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505237 · Cited by 236
Görgün, G., Calabrese, E., Soydan, E., Hideshima, T., Perrone, G., Bandi, M., Cirstea, D., Santo, L., Hu, Y., Tai, Y.-T., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279893 · Cited by 230
Baz, R., Li, L., Kottke-Marchant, K., Srkalovic, G., McGowan, B., Yiannaki, E., Karam, M. A., Faiman, B., Jawde, R. A., Andresen, S., et al. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.12.1568 · Cited by 228
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Shah, J. J., Stadtmauer, E. A., Abonour, R., Cohen, A. D., Bensinger, W. I., Gasparetto, C., Kaufman, J. L., Lentzsch, S., Vogl, D. T., Gomes, C. L., et al. (2015) · Blood · doi:10.1182/blood-2015-05-643320 · Cited by 226
The Saga of Thalidomide: Neuropathy to Embryopathy, with Case Reports of Congenital Anomalies
Mellin, G. W., & Katzenstein, M. (1962) · New England Journal of Medicine · doi:10.1056/nejm196212132672407 · Cited by 224
Zhu, Y. X., Braggio, E., Shi, C.-X., Kortuem, K. M., Bruins, L. A., Schmidt, J. E., Chang, X.-B., Langlais, P., Luo, M., Jedlowski, P., et al. (2014) · Blood · doi:10.1182/blood-2014-02-557819 · Cited by 213
Breitkreutz, I., Raab, M. S., Vallet, S., Hideshima, T., Raje, N., Mitsiades, C., Chauhan, D., Okawa, Y., Munshi, N. C., Richardson, P. G., et al. (2008) · Leukemia · doi:10.1038/leu.2008.174 · Cited by 209
Leleu, X., Attal, M., Arnulf, B., Moreau, P., Traulle, C., Marit, G., Mathiot, C., Petillon, M. O., Macro, M., Roussel, M., et al. (2013) · Blood · doi:10.1182/blood-2012-09-452375 · Cited by 206
Wang, M., Fowler, N., Wagner-Bartak, N., Feng, L., Romaguera, J., Neelapu, S. S., Hagemeister, F., Fanale, M., Oki, Y., Pro, B., et al. (2013) · Leukemia · doi:10.1038/leu.2013.95 · Cited by 203
Yee, A. J., Bensinger, W. I., Supko, J. G., Voorhees, P. M., Berdeja, J. G., Richardson, P. G., Libby, E. N., Wallace, E. E., Birrer, N. E., Burke, J. N., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30375-8 · Cited by 203
Mailankody, S., Pfeiffer, R. M., Kristinsson, S. Y., Korde, N., Bjorkholm, M., Goldin, L. R., Turesson, I., & Landgren, O. (2011) · Blood · doi:10.1182/blood-2011-05-355743 · Cited by 200
Lacy, M. Q., Hayman, S. R., Gertz, M. A., Short, K. D., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2010) · Leukemia · doi:10.1038/leu.2010.190 · Cited by 197
Zonder, J. A., Crowley, J., Hussein, M. A., Bolejack, V., Moore, D. F., Whittenberger, B. F., Abidi, M. H., Durie, B. G. M., & Barlogie, B. (2010) · Blood · doi:10.1182/blood-2010-08-303487 · Cited by 194
Cavo, M., Zamagni, E., Tosi, P., Cellini, C., Cangini, D., Tacchetti, P., Testoni, N., Tonelli, M., Vivo, A. D., Palareti, G., et al. (2004) · PubMed · Cited by 191
Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.
Palumbo, A., Giaccone, L., Bertola, A., Pregno, P., Bringhen, S., Rus, C., Triolo, S., Gallo, E., Pileri, A., & Boccadoro, M. (2001) · PubMed · Cited by 191
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
Raje, N., Kumar, S., Hideshima, T., Ishitsuka, K., Chauhan, D., Mitsiades, C., Podar, K., Le Gouill, S., Richardson, P., Munshi, N. C., et al. (2004) · Blood · doi:10.1182/blood-2004-06-2281 · Cited by 187
Eichner, R., Heider, M., Fernández-Sáiz, V., van Bebber, F., Garz, A.-K., Lemeer, S., Rudelius, M., Targosz, B.-S., Jacobs, L., Knorn, A.-M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4128 · Cited by 183
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
Palumbo, A., Ambrosini, M. T., Benevolo, G., Pregno, P., Pescosta, N., Callea, V., Cangialosi, C., Caravita, T., Morabito, F., Musto, P., et al. (2007) · Blood · doi:10.1182/blood-2006-08-042275 · Cited by 182
Richardson, P. G., Xie, W., Jagannath, S., Jakubowiak, A., Lonial, S., Raje, N. S., Alsina, M., Ghobrial, I. M., Schlossman, R. L., Munshi, N. C., et al. (2014) · Blood · doi:10.1182/blood-2013-07-517276 · Cited by 182
Benson, D. M., Cohen, A. D., Jagannath, S., Munshi, N. C., Spitzer, G., Hofmeister, C. C., Efebera, Y. A., Andre, P., Zerbib, R., & Caligiuri, M. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0304 · Cited by 180
Wang, M., Dimopoulos, M. A., Chen, C., Cibeira, M. T., Attal, M., Spencer, A., Rajkumar, S. V., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2008) · Blood · doi:10.1182/blood-2008-02-141614 · Cited by 176 · cited 1×
“With respect to IMiD cross-resistance, patients who have previously been exposed to thalidomide have a lower overall response rate to lenalidomide/dexamethasone than thalidomide-naı̈ve patients [124] and approximately 30–47% of patients who are refractory to lenalidomide respond to pomalidomide/dexamethasone [76, 125].”
Lee, C.-K., Barlogie, B., Munshi, N., Zangari, M., Fassas, A., Jacobson, J., van Rhee, F., Cottler-Fox, M., Muwalla, F., & Tricot, G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.055 · Cited by 175
Hernandez-Ilizaliturri, F. J., Reddy, N., Holkova, B., Ottman, E., & Czuczman, M. S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0577 · Cited by 174
Srkalovic, G., Cameron, M. G., Rybicki, L., Deitcher, S. R., Kattke‐Marchant, K., & Hussein, M. A. (2004) · Cancer · doi:10.1002/cncr.20405 · Cited by 172
Dimopoulos, M. A., Palumbo, A., Corradini, P., Cavo, M., Delforge, M., Di Raimondo, F., Weisel, K. C., Oriol, A., Hansson, M., Vacca, A., et al. (2016) · Blood · doi:10.1182/blood-2016-02-700872 · Cited by 165
Zhu, D., Corral, L. G., Fleming, Y. W., & Stein, B. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0512-7 · Cited by 164
Richardson, P. G., Siegel, D., Baz, R., Kelley, S. L., Munshi, N. C., Laubach, J., Sullivan, D., Alsina, M., Schlossman, R., Ghobrial, I. M., et al. (2013) · Blood · doi:10.1182/blood-2012-08-450742 · Cited by 162
Richardson, P. G., Weller, E., Jagannath, S., Avigan, D. E., Alsina, M., Schlossman, R. L., Mazumder, A., Munshi, N. C., Ghobrial, I. M., Doss, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2679 · Cited by 162 · cited 1×
“As with thalidomide, lenalidomide has been studied in combination with multiple different agents including alkylating agents (low-dose cyclophosphamide [49–51], bendamustine [52, 53], melphalan [54]), liposomal doxorubicin [55, 56], proteasome inhibitors (bortezomib [57, 58], carfilzomib [59–61], ixazomib [62]), HDAC…”
García-Sanz, R., González-Porras, J. R., Hernández, J. M., Polo-Zarzuela, M., Sureda, A., Barrenetxea, C., Palomera, L., López, R., Grande-García, C., Alegre, A., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403322 · Cited by 159
Baz, R. C., Martin, T. G., Lin, H.-Y., Zhao, X., Shain, K. H., Cho, H. J., Wolf, J. L., Mahindra, A., Chari, A., Sullivan, D. M., et al. (2016) · Blood · doi:10.1182/blood-2015-11-682518 · Cited by 159
Badoux, X. C., Keating, M. J., Wen, S., Wierda, W. G., O'Brien, S. M., Faderl, S., Sargent, R., Burger, J. A., & Ferrajoli, A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8623 · Cited by 158
Hsu, A. K., Quach, H., Tai, T., Prince, H. M., Harrison, S. J., Trapani, J. A., Smyth, M. J., Neeson, P., & Ritchie, D. S. (2011) · Blood · doi:10.1182/blood-2010-04-278432 · Cited by 158
Dimopoulos, M. A., Hamilos, G., Zomas, A., Gika, D., Efstathiou, E., Grigoraki, V., Poziopoulos, C., Xilouri, I., Zorzou, M. P., Anagnostopoulos, N. I., et al. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200326 · Cited by 150
Dimopoulos, M. A., Richardson, P. G. G., Brandenburg, N. A., Yu, Z., Weber, D. M., Niesvizky, R., & Morgan, G. J. (2012) · Blood · doi:10.1182/blood-2011-08-373514 · Cited by 149
Baz, R., Walker, E., Karam, M. A., Choueiri, T. K., Jawde, R. M. A., Bruening, K., Reed, J., Faiman, B. M., Ellis, Y., Brand, C., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl313 · Cited by 147
Cortés, M., & Georgopoulos, K. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031571 · Cited by 146
Kropff, M. H., Lang, N., Bisping, G., Dominé, N., Innig, G., Hentrich, M., Mitterer, M., Südhoff, T., Fenk, R. R., Straka, C., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04473.x · Cited by 140
Pineda-Roman, M., Zangari, M., van Rhee, F., Anaissie, E., Szymonifka, J., Hoering, A., Petty, N., Crowley, J., Shaughnessy, J., Epstein, J., et al. (2008) · Leukemia · doi:10.1038/leu.2008.99 · Cited by 139
Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
Lagrue, K., Carisey, A. F., Morgan, D. J., Chopra, R., & Davis, D. M. (2015) · Blood · doi:10.1182/blood-2015-01-625004 · Cited by 139
Wang, M. L., Martin, T. G., Bensinger, W., Alsina, M., Siegel, D. S. D., Kavalerchik, E., Huang, M., Orlowski, R. Z., & Niesvizky, R. (2013) · Blood · doi:10.1182/blood-2013-07-511170 · Cited by 131
Heintel, D., Rocci, A., Ludwig, H., Bolomsky, A., Caltagirone, S., Schreder, M., Pfeifer, S., Gisslinger, H., Zojer, N., Jäger, U., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12338 · Cited by 128
Lentzsch, S., O'Sullivan, A., Kennedy, R. C., Abbas, M., Dai, L., Pregja, S. L., Burt, S., Boyiadzis, M. M., Roodman, G. D., Mapara, M. Y., et al. (2012) · Blood · doi:10.1182/blood-2011-12-395715 · Cited by 126
Zervas, K., Dimopoulos, M. A., Hatzicharissi, E., Anagnostopoulos, Α., Papaioannou, M., Mitsouli, C., Panagiotidis, P., Korantzis, J., Tzilianos, M., & Maniatis, A. G. (2003) · Annals of Oncology · doi:10.1093/annonc/mdh026 · Cited by 126
Zweegman, S., van der Holt, B., Mellqvist, U., Salomo, M., Bos, G. M. J., Levin, M., Visser-Wisselaar, H. A., Hansson, M., van der Velden, A. W. G., Deenik, W., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679415 · Cited by 124
Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration
Hoffmann, M., Kasserra, C., Reyes, J., Schafer, P., Kosek, J., Capone, L., Parton, A., Kim-Kang, H., Surapaneni, S., & Kumar, G. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2040-6 · Cited by 121
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma
Wang, M., Giralt, S., Delasalle, K. B., Handy, B. C., & Alexanian, R. (2007) · Hematology · doi:10.1080/10245330701214236 · Cited by 117
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
Plesner, T., Arkenau, H., Gimsing, P., Krejcik, J., Lemech, C., Minnema, M. C., Lassen, U., Laubach, J. P., Palumbo, A. P., Lisby, S., et al. (2016) · Blood · doi:10.1182/blood-2016-07-726729 · Cited by 117
Kyriakou, C. A., Thomson, K. J., D’Sa, S., Flory, A. J., Hanslip, J., Goldstone, A. H., & Yong, K. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05521.x · Cited by 114
Zinzani, P. L., Pellegrini, C., Gandolfi, L., Stefoni, V., Quirini, F., Derenzini, E., Broccoli, A., Argnani, L., Pileri, S. A., & Baccarani, M. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.02.001 · Cited by 114
The clinical significance of cereblon expression in multiple myeloma
Schuster, S. R., Kortuem, K. M., Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Ahmann, G., Kumar, S., Rajkumar, S. V., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2013.08.015 · Cited by 113
Nowakowski, G. S., LaPlant, B. R., Habermann, T. M., Rivera, C. E., Macon, W. R., Inwards, D. J., Micallef, I. N., Johnston, P. B., Porrata, L. F., Ansell, S. M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.165 · Cited by 109
Hussein, M. A., Baz, R., Srkalović, G., Agrawal, N. R., Suppiah, R., Hsi, E. D., Andresen, S. W., Karam, M. A., Reed, J., Faiman, B. M., et al. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.7.889 · Cited by 108
Offidani, M. (2006) · Blood · doi:10.1182/blood-2006-03-013086 · Cited by 103
Stewart, A. K., Jacobus, S. J., Fonseca, R., Weiss, M., Callander, N. S., Chanan-Khan, A. A., & Rajkumar, S. V. (2015) · Blood · doi:10.1182/blood-2014-12-613927 · Cited by 96
Thalidomide Metabolism and Hydrolysis: Mechanisms and Implications
Lepper, E. R., Smith, N. F., Cox, M. C., Scripture, C. D., & Figg, W. D. (2006) · Current Drug Metabolism · doi:10.2174/138920006778017777 · Cited by 95
Fionda, C., Abruzzese, M. P., Zingoni, A., Cecere, F., Vulpis, E., Peruzzi, G., Soriani, A., Molfetta, R., Paolini, R., Ricciardi, M. R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4603 · Cited by 94
Li, S., Pal, R., Monaghan, S. A., Schafer, P. H., Ouyang, H., Mapara, M. Y., Galson, D. L., & Lentzsch, S. (2011) · Blood · doi:10.1182/blood-2010-10-314278 · Cited by 94
Attal, M., Lauwers, V. C., Marit, G., Caillot, D., Facon, T. T. F., Hulin, C., Moreau, P., Mathiot, C., Roussel, M., Payen, C., et al. (2010) · Blood · doi:10.1182/blood.v116.21.310.310 · Cited by 94
Larocca, A., Montefusco, V., Bringhen, S., Rossi, D., Crippa, C., Mina, R., Galli, M., Marcatti, M., Verde, G. L., Giuliani, N., et al. (2013) · Blood · doi:10.1182/blood-2013-03-488676 · Cited by 90
Albertsson‐Lindblad, A., Kolstad, A., Laurell, A., Räty, R., Grønbæk, K., Sundberg, J., Pedersen, L. B., Ralfkiaer, E. M., Karjalainen‐Lindsberg, M., Sundström, C., et al. (2016) · Blood · doi:10.1182/blood-2016-03-704023 · Cited by 90
McCarthy, P. L., Owzar, K., Anderson, K. C., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Giralt, S., Stadtmauer, E. A., Richardson, P. G. G., Weisdorf, D. J., et al. (2010) · Blood · doi:10.1182/blood.v116.21.37.37 · Cited by 89
Self-citationChen, N., Wen, L., Lau, H. S. H., Surapaneni, S., & Kumar, G. N. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1760-3 · Cited by 88
Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases
Xu, Y., Li, J., Ferguson, G. D., Mercurio, F., Khambatta, G., Morrison, L., Lopez‐Girona, A., Corral, L. G., Webb, D. R., Bennett, B. L., et al. (2009) · Blood · doi:10.1182/blood-2009-02-200543 · Cited by 88
Miguel, J. F. S., Mateos, M., Shah, J. J., Ocio, E. M., Rodríguez‐Otero, P., Reece, D. E., Munshi, N. C., Avigan, D., Ge, Y., Balakumaran, A., et al. (2015) · Blood · doi:10.1182/blood.v126.23.505.505 · Cited by 88
Henry, J. Y., Labarthe, M., Meyer, B., Prokar Dasgupta, A., Dalgleish, A. G., & Galustian, C. (2013) · Immunology · doi:10.1111/imm.12087 · Cited by 87
Niesvizky, R., Martin, T. G., Bensinger, W., Alsina, M., Siegel, D. S. D., Kunkel, L., Wong, A., Lee, S., Orlowski, R. Z., & Wang, M. L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3352 · Cited by 86
Olsson, L., & Johansson, B. (2015) · British Journal of Haematology · doi:10.1111/bjh.13342 · Cited by 85
Paludo, J., Mikhael, J. R., LaPlant, B. R., Halvorson, A. E., Kumar, S. K., Gertz, M. A., Hayman, S. R., Buadi, F. K., Dispenzieri, A. A., Lust, J. A., et al. (2017) · Blood · doi:10.1182/blood-2017-05-782961 · Cited by 80
Bolzoni, M., Storti, P., Bonomini, S., Todoerti, K., Guasco, D., Toscani, D., Agnelli, L., Neri, A., Rizzoli, V., & Giuliani, N. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.11.005 · Cited by 77
Zangari, M., Fink, L. M., Zhan, F., & Tricot, G. J. K. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.03.006 · Cited by 77
Offidani, M., Corvatta, L., Marconi, M., Visani, G., Alesiani, F., Brunori, M., Galieni, P., Catarini, M., Burattini, M., Centurioni, R., et al. (2006) · PubMed · Cited by 77
Tuscano, J. M., Dutia, M. P., Chee, K. G., Brunson, A. M., Reed‐Pease, C., Abedi, M., Welborn, J. L., & OʼDonnell, R. T. (2014) · British Journal of Haematology · doi:10.1111/bjh.12755 · Cited by 76
Usmani, S. Z., Sexton, R. E., Hoering, A., Heuck, C. J., Nair, B. P., Waheed, S., Alsayed, Y. M., Chauhan, N., Ahmad, N., Atrash, S., et al. (2012) · Blood · doi:10.1182/blood-2012-04-421883 · Cited by 75
Corso, A., Lorenzi, A., Terulla, V., Air�, F., Varettoni, M., Mangiacavalli, S., Zappasodi, P., Rusconi, C., & Lazzarino, M. (2004) · Annals of Hematology · doi:10.1007/s00277-004-0891-6 · Cited by 73
Razavi, P., Rand, K. A., Cozen, W., Chanan-Khan, A. A., Usmani, S. Z., & Ailawadhi, S. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.19 · Cited by 73
Sonneveld, P., Asselbergs, E., Zweegman, S., van der Holt, B., Kersten, M. J., Vellenga, E., van Marwijk-Kooy, M., Broyl, A., de Weerdt, O., Lonergan, S., et al. (2014) · Blood · doi:10.1182/blood-2014-05-576256 · Cited by 68
Assessment of the effectiveness of animal developmental toxicity testing for human safety
Newman, L. M., Johnson, E. M., & STAPLES, R. E. (1993) · Reproductive Toxicology · doi:10.1016/0890-6238(93)90025-3 · Cited by 65
Kumar, S. K., Lacy, M. Q., Hayman, S. R., Stewart, K., Buadi, F. K., Allred, J. B., Laumann, K. M., Greipp, P. R., Lust, J. A., Gertz, M. A., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.22053 · Cited by 64
Attal, M., Palumbo, A., Holstein, S. A., Lauwers-Cances, V., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Anderson, K. C., Caillot, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.8001 · Cited by 63
Self-citationMusallam, K. M., Dahdaleh, F. S., Shamseddine, A. I., & Taher, A. T. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.09.008 · Cited by 63
Chong, E. A., Ahmadi, T., Aqui, N. A., Svoboda, J., Nasta, S. D., Mato, A. R., Walsh, K. M., & Schuster, S. J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2221 · Cited by 63
A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma
Chari, A., Cho, H. J., Dhadwal, A., Morgan, G., La, L., Zarychta, K., Catamero, D., Florendo, E., Stevens, N., Verina, D., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007427 · Cited by 61
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma
Palumbo, A., Avonto, I., Bruno, B., Ambrosini, M. T., Bringhen, S., Cavallo, F., Falco, P., & Boccadoro, M. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00610.x · Cited by 60
Chari, A., Lonial, S., Suvannasankha, A., Fay, J. W., Arnulf, B., Ifthikharuddin, J. J., Qin, X., Masterson, T. J., Nottage, K. A., Schecter, J. M., et al. (2015) · Blood · doi:10.1182/blood.v126.23.508.508 · Cited by 59
Schey, S., Morgan, G. J., Ramasamy, K., Hazel, B., Ładoń, D., Corderoy, S., Jenner, M. W., Phekoo, K. J., Boyd, K. D., & Davies, F. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08250.x · Cited by 57
Nijhof, I. S., Franssen, L. E., Levin, M., Bos, G. M. J., Broijl, A., Klein, S. K., Koene, H. R., Bloem, A. C., Beeker, A., Faber, L. M., et al. (2016) · Blood · doi:10.1182/blood-2016-07-729236 · Cited by 57
Liu, Y., Huang, X., He, X., Zhou, Y., Jiang, X., Chen‐Kiang, S., Jaffrey, S. R., & Xu, G. (2015) · The FASEB Journal · doi:10.1096/fj.15-274050 · Cited by 56
Thalidomide protects endothelial cells from doxorubicin‐induced apoptosis but alters cell morphology
Kaushal, V., Kaushal, G. P., Melkaveri, S. N., & Mehta, P. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7933.2003.00573.x · Cited by 56
Palumbo, A. P., Delforge, M., Catalano, J. V., Hájek, R., Kropff, M. H., Petrucci, M. T., Yu, Z., Herbein, L., Mei, J. M., Jacques, C. J., et al. (2010) · Blood · doi:10.1182/blood.v116.21.622.622 · Cited by 56
Badros, A. Z., Kocoglu, M. H., Ma, N., Rapoport, A. P., Lederer, E., Philip, S., Lesho, P., Dell, C. A., Hardy, N. M., Yared, J. A., et al. (2015) · Blood · doi:10.1182/blood.v126.23.506.506 · Cited by 55
Attal, M., Lauwers‐Cancès, V., Marit, G., Caillot, D., Facon, T. T. F., Hulin, C., Moreau, P., Mathiot, C., Roussel, M., Payen, C., et al. (2013) · Blood · doi:10.1182/blood.v122.21.406.406 · Cited by 54
Miguel, J. F. S., Weisel, K. C., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Moreau, P., Baños, A., Oriol, A., Garderet, L., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.125864 · Cited by 53
Primary function analysis of human mental retardation related gene CRBN
Xin, W., Xiaohua, N., Chen, P., Chen, X., Sun, Y., & Wu, Q. (2007) · Molecular Biology Reports · doi:10.1007/s11033-007-9077-3 · Cited by 52
Hou, J., Du, X., Jin, J., Cai, Z., Chen, F., Zhou, D.-B., Yu, L., Ke, X., Li, X., Wu, D., et al. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-41 · Cited by 50
Mateos, M., Granell, M., Oriol, A., Martínez‐López, J., Bladé, J., Hernández, M., Martín, J., Gironella, M., Lynch, M. J., Bleickardt, E. W., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14263 · Cited by 49
Mikhael, J. R., Reeder, C. B., Libby, E. N., Costa, L. J., Bergsagel, P. L., Buadi, F. K., Mayo, A., Reddy, S. K. N., Gano, K., Dueck, A. C., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13296 · Cited by 48
New Cancers after Autotransplantations for Multiple Myeloma
Mahindra, A. K., Raval, G. G., Mehta, P., Brazauskas, R., Zhang, M., Zhong, X., Bird, J. M., Freytes, C. O., Hale, G. A., Herzig, R. H., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.12.028 · Cited by 47
Ahmadi, T., Chong, E. A., Gordon, A., Aqui, N. A., Nasta, S. D., Svoboda, J., Mato, A. R., & Schuster, S. J. (2013) · Cancer · doi:10.1002/cncr.28405 · Cited by 46
Second Primary Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Krishnan, A. Y., Mei, M. G., Sun, C., Thomas, S. H., Teh, J. B., Kang, T., Htut, M., Somlo, G., Sahebi, F., Forman, S. J., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.09.023 · Cited by 45
Rossi, A., Mark, T. M., Jayabalan, D. S., Christos, P. J., Zafar, F., Pekle, K. A., Pearse, R. N., Chen‐Kiang, S., Coleman, M., & Niesvizky, R. (2013) · Blood · doi:10.1182/blood-2012-08-448563 · Cited by 41
Lapalombella, R., Gowda, A. C., Joshi, T., Mehter, N. S., Cheney, C. M., Lehman, A., Chen, C., Johnson, A. J., Caligiuri, M. A., Tridandapani, S., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07548.x · Cited by 38
Tzeng, H.-E., Lin, C., Tsai, C., Tang, C.-H., Hwang, W. L., Cheng, Y.-W., Sung, F. C., & Chung, C. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068041 · Cited by 38
Ciolli, S., Leoni, F., Gigli, F., Rigacci, L., & Bosi, A. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500272721 · Cited by 37
Richter, J. R., Martin, T. G., Vij, R., Cole, C. E., Atanackovic, D., Zonder, J. A., Kaufman, J. L., Mikhael, J. R., Bensinger, W., Dimopoulos, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.8005 · Cited by 36
Gandhi, A. K., Shi, T., Li, M., Jungnelius, U., Romano, A., Tabernero, J. M., Siena, S., Schafer, P. H., & Chopra, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080437 · Cited by 34
Martin, T. G., Richter, J. R., Vij, R., Cole, C. E., Atanackovic, D., Zonder, J. A., Kaufman, J. L., Bensinger, W., Dimopoulos, M. A., Miguel, J. F. S., et al. (2015) · Blood · doi:10.1182/blood.v126.23.509.509 · Cited by 34
Bertino, E. M., McMichael, E. L., Mo, X. M., Trikha, P., Davis, M. E., Paul, B. K., Grever, M. R., Carson, W. E., & Otterson, G. A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0879 · Cited by 32
Hovenga, S., Daenen, S. M. G. J., de Wolf, J. T. M., Imhoff, G. W. V., Kluin‐Nelemans, H. C., Sluiter, W. J., & Vellenga, E. (2004) · Annals of Hematology · doi:10.1007/s00277-004-0981-5 · Cited by 31
Lacy, M. Q., LaPlant, B. R., Laumann, K. M., Kumar, S. K., Gertz, M. A., Hayman, S. R., Buadi, F. K., Dispenzieri, A. A., Lust, J. A., Kapoor, P., et al. (2014) · Blood · doi:10.1182/blood.v124.21.304.304 · Cited by 30
Kumar, S. K., Krishnan, A. Y., LaPlant, B. R., Laumann, K. M., Roy, V., Zimmerman, T. M., Gertz, M. A., Buadi, F. K., Stockerl-Goldstein, K. E., Birgin, A., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24181 · Cited by 25
Thalidomide for dermatology: a review of clinical uses and adverse effects
Faver, I. R., Guerra, S. G., Su, W. P. D., & el‐Azhary, R. A. (2004) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2004.02445.x · Cited by 23
Holstein, S. A., Owzar, K., Richardson, P. G. G., Jiang, C., Hofmeister, C. C., Hassoun, H., Hurd, D. D., Stadtmauer, E. A., Giralt, S., Devine, S. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8523 · Cited by 21
Self-citationMaintenance Therapy for Multiple Myeloma
McCarthy, P. L., & Palumbo, A. P. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.06.006 · Cited by 19
Self-citationRichardson, P. G. G., Hofmeister, C. C., Raje, N. S., Siegel, D. S. D., Lonial, S., Laubach, J. P., Efebera, Y. A., Vesole, D. H., Nooka, A. K., Rosenblatt, J. M., et al. (2015) · Blood · doi:10.1182/blood.v126.23.3036.3036 · Cited by 13
Baz, R., Shain, K. H., Hussein, M. A., Lee, J., Sullivan, D. M., Oliver, E. F., Nardelli, L. A., Nodzon, L., Zhao, X., Ochoa-Bayona, J. L., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23587 · Cited by 10
Rollison, D. E. M., Shain, K. H., Lee, J., Hampras, S. S., Fulp, W. J., Fisher, K. J., Ali, N. H. A., Padron, E., Lancet, J. E., Xu, Q., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.721 · Cited by 6
Cited by
Advancing targeted protein degradation for cancer therapy
Dale, B., Cheng, M., Park, K.-S., Kaniskan, H. Ü., Xiong, Y., & Jin, J. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00365-x · Cited by 632
Targeted protein degradation: from mechanisms to clinic
Tsai, J. M., Nowak, R. P., Ebert, B. L., & Fischer, E. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00729-9 · Cited by 438
Usmani, S. Z., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Gavriatopoulou, M., Oriol, A., Rabin, N., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00579-9 · Cited by 171
Bone marrow inflammation in haematological malignancies
de Jong, M. M. E., Chen, L., Raaijmakers, M. H. G. P., & Cupedo, T. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01003-x · Cited by 54
Cippitelli, M., Stabile, H., Kosta, A., Petillo, S., Gismondi, A., Santoni, A., & Fionda, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031103 · Cited by 42
Metadata
- Authors
- Holstein, S. A., & McCarthy, P. L.
- Venue
- Drugs
- Published
- 2017-02-16
- Volume
- 77
- Issue
- 5
- Pages
- 505-520
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2588162473
- Cited by
- 255
- References
- 191
- FWCI
- 9.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.